ClinicalTrials.gg
RecruitingNCT07876609Updated Oct 19, 2026

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1203 in Advanced Solid Tumors.

A Phase 1 interventional study of BA1203 in Solid Tumors, sponsored by Shandong Boan Biotechnology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Shandong Boan Biotechnology Co., Ltd (part of Luye Pharma Group Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 19, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1203 in participants with advanced solid tumors.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Shandong Boan Biotechnology Co., Ltd is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide written and to comply with the study protocol;
  2. Subject with or cytologically confirmed advanced and/or solid tumors who have progressed on all standard therapies, are intolerant to Standard-Of-Care (SOC), and/or are non-amenable to SOC;
  3. At least one according to Response Evaluation Criteria for Solid Tumors version 1.1 ( v1.1);
  4. Patients with colorectal cancer must have a microsatellite instability (MSI) test report, and patients with other tumor types must have a prior Programmed Death-Ligand 1 () histopathological examination report; if unavailable, tumor tissue specimens must be provided for the above tests.;
  5. >=12 weeks;
  6. (ECOG) performance status of 0 or 1;
  7. Adequate major organ function;
  8. Women of must have a negative pregnancy test within 7 days prior to the first dose: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective methods;
  9. Men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods and refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  1. Patients with primary central nervous system tumors or new or symptomatic central nervous system .
  2. Patients with a known history of another within 5 years prior to signing the .
  3. Patients with significant cardiovascular and cerebrovascular diseases.
  4. Presence of any of the following within 8 weeks before the first dose: symptomatic radiation pneumonitis, radiation esophagitis, or radiation-induced colitis/proctitis; interstitial lung disease; pulmonary disease with severe obstructive ventilatory impairment; unhealed peptic ulcer; cirrhosis-related complications; chronic enteritis; ischemic necrotizing enteritis; gastrointestinal obstruction; tendency to gastrointestinal bleeding or high risk of gastrointestinal perforation; pancreatitis requiring treatment; arterial or venous thrombotic disease; chronic nephritis; or nephrotic syndrome.
  5. Any active disease, or autoimmune or inflammatory disease requiring therapy.
  6. History of Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug-induced syndrome (DIHS).
  7. History of hematopoietic stem cell transplantation or organ transplantation, or currently awaiting transplantation.
  8. Immune-related adverse events during prior antitumor therapy that make the patient no longer suitable for continued immunotherapy.
  9. Prior treatment with Programmed Cell Death Protein 1 / Interleukin-2 or Programmed Cell Death Protein 1 / Interleukin-15 agents.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    BA1203

    Participants will receive BA1203 once every 2 weeks (Q2W), until confirmed progression, death, unaccepted toxicity, initiation of other antitumor therapies, or any other conditions requiring treatment discontinuation, and the maximum duration of administration was no more than 2 years.

    Drug: BA1203

Interventions

  • DrugBA1203

    intravenous (IV) once every 2 weeks (Q2W).

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) , immune-related AEs(irAEs), infusion-related reactions (IRRs), AEs of special interest (AESIs)

    Time frame: Through 28 days after the last study treatment

  2. Incidence and severity of dose limiting toxicities in each dose cohort, and maximum tolerated dose

    Time frame: Through 28 days after the last study treatment

  3. Recommended phase 2 dose of BA1203

    Time frame: Through 28 days after the last study treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAt least one measurable lesion according to Response Evaluation Criteria for Solid Tumors version 1.1 (RECIST v1.1);
  • EditedPatients with colorectal cancer must have a microsatellite instability (MSI) test report, and patients with other tumor types must have a prior Programmed Death-Ligand 1 (PD-L1) histopathological examination report; if unavailable, tumor tissue specimens must be provided for the above tests.;
Exclusion criteria
  • EditedPatients with primary CNScentral nervous system tumors or new or symptomatic CNScentral nervous system metastases.
  • EditedPrior treatment with PD-Programmed Cell Death Protein 1 /IL Interleukin-2 or PD-Programmed Cell Death Protein 1 /IL Interleukin-15 agents.
Oct 19, 2026
Primary outcomes
1 edited, 2 added, 2 removed
What changed in the outcomes
  • EditedIncidence and severity of DLTsdose limiting toxicities in each dose cohort, and MTDmaximum tolerated doseTime frame: Through 28 days after the last study treatment
  • AddedIncidence and severity of adverse events (AEs) , immune-related AEs(irAEs), infusion-related reactions (IRRs), AEs of special interest (AESIs)Time frame: Through 28 days after the last study treatment
  • AddedRecommended phase 2 dose of BA1203Time frame: Through 28 days after the last study treatment
  • RemovedIncidence and severity of adverse events (AEs), TEAEs, and SAEs, irAEs, IRRs, AESIs, and adverse events leading to dose reduction, treatment interruption, permanent discontinuation, and death (according to NCI CTCAE 6.0)Time frame: Through 28 days after the last study treatment
  • RemovedRP2D of BA1203Time frame: Through 28 days after the last study treatment
Oct 19, 2026
Registered
First appeared on the registry
Oct 15, 2026
Show all 2 updates
  1. Oct 19, 2026
    Eligibility 2 inclusion criteria edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAt least one measurable lesion according to Response Evaluation Criteria for Solid Tumors version 1.1 (RECIST v1.1);
    • EditedPatients with colorectal cancer must have a microsatellite instability (MSI) test report, and patients with other tumor types must have a prior Programmed Death-Ligand 1 (PD-L1) histopathological examination report; if unavailable, tumor tissue specimens must be provided for the above tests.;
    Exclusion criteria
    • EditedPatients with primary CNScentral nervous system tumors or new or symptomatic CNScentral nervous system metastases.
    • EditedPrior treatment with PD-Programmed Cell Death Protein 1 /IL Interleukin-2 or PD-Programmed Cell Death Protein 1 /IL Interleukin-15 agents.
    Primary outcomes 1 edited, 2 added, 2 removed
    What changed in the outcomes
    • EditedIncidence and severity of DLTsdose limiting toxicities in each dose cohort, and MTDmaximum tolerated doseTime frame: Through 28 days after the last study treatment
    • AddedIncidence and severity of adverse events (AEs) , immune-related AEs(irAEs), infusion-related reactions (IRRs), AEs of special interest (AESIs)Time frame: Through 28 days after the last study treatment
    • AddedRecommended phase 2 dose of BA1203Time frame: Through 28 days after the last study treatment
    • RemovedIncidence and severity of adverse events (AEs), TEAEs, and SAEs, irAEs, IRRs, AESIs, and adverse events leading to dose reduction, treatment interruption, permanent discontinuation, and death (according to NCI CTCAE 6.0)Time frame: Through 28 days after the last study treatment
    • RemovedRP2D of BA1203Time frame: Through 28 days after the last study treatment
  2. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876609
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion